Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ciclesonide is a synthetic, nonhalogenated corticosteroid (glucocorticoid) used primarily as an inhaled or intranasal agent for the prevention and control of asthma and allergic rhinitis symptoms. It acts as a prodrug that is enzymatically converted in the body to its active metabolite, des-ciclesonide (RM1), which has high affinity for the glucocorticoid receptor. By binding to these receptors, ciclesonide exerts potent anti-inflammatory effects through inhibition of leukocyte infiltration, suppression of inflammatory mediators (such as prostaglandins and leukotrienes), and modulation of gene expression involved in immune responses. Ciclesonide is not effective for acute asthma attacks but reduces airway inflammation when used regularly[1][2][3][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ciclesonide.